105
Amylyx Pharmaceuticals, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
382
FY23:
465
FY24:
189
FY25:
324
(positive)
Change from FY21 to FY25
millions USD
FY21:
0.66
FY22:
9.32
FY23:
52.8
FY24:
4.20
FY25:
8.97
Total assets
Change from FY21 to FY25
millions USD
FY21:
106
FY22:
391
FY23:
517
FY24:
194
FY25:
333
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
17.4
FY22:
46.6
FY23:
82.0
FY24:
28.4
FY25:
22.7
(negative)
Change from FY21 to FY25
millions USD
FY21:
0.04
FY22:
4.24
FY23:
1.98
FY24:
0.46
FY25:
4.70
(positive)
Change from FY21 to FY25
millions USD
FY21:
−151
FY22:
341
FY23:
433
FY24:
165
FY25:
305
Total liabilities & equity
Change from FY22 to FY25
millions USD
FY21:
–
FY22:
391
FY23:
517
FY24:
194
FY25:
333
All amounts in millions USD